AmerisourceBergen Acquires Minority Interest in Profarma Distribuidora de Produtos Farmacêuticos S.A.

  AmerisourceBergen Acquires Minority Interest in Profarma Distribuidora de
  Produtos Farmacêuticos S.A.

       Establishes a Joint Venture for Specialty Distribution in Brazil

Business Wire

VALLEY FORGE, Pa. -- March 24, 2014

AmerisourceBergen Corporation (NYSE:ABC) today announced that it has reached a
definitive agreement to acquire a minority stake in Profarma Distribuidora de
Produtos Farmacêuticos S.A. (Profarma), a leading pharmaceutical wholesaler in
Brazil. In addition, AmerisourceBergen and Profarma will establish a joint
venture for specialty distribution and services. The Company expects to invest
a total of approximately $100 million, and the transaction is expected to
close in the June quarter of 2014. AmerisourceBergen does not expect the
transaction to have a meaningful impact to its adjusted earnings per share
from continuing operations for fiscal 2014.

“We are very excited to partner with Profarma as we continue to expand our
reach into growing international markets,” said Steven H. Collis, President
and Chief Executive Officer of AmerisourceBergen. “With its long-term
macroeconomic growth outlook, favorable demographics, and increasing access to
healthcare services and specialty pharmaceuticals, the Brazilian market
affords us a tremendous opportunity to expand our international offerings.
Profarma’s success in the wholesale distribution, chain and independent
retail, and specialty markets, combined with our expertise in specialty
distribution and manufacturer services provides a compelling opportunity to
shape the delivery of healthcare in Brazil.”

Sammy Birmarcker, Chief Executive Officer of Profarma, highlighted the
positive effects that the association with AmerisourceBergen should bring for
the operations of Profarma Specialty, such as access to new medicines,
equipment, services and practices that currently do not exist in Brazil. “We
hope the country will soon be able to benefit from the technological advances
that are already available to the specialty pharmaceutical distribution
industry in more evolved markets abroad,” emphasized Birmarcker. “We believe
that the experience acquired by Profarma over the course of its 52 years of
activities, combined with the technology and expertise of AmerisourceBergen in
rendering new services, will provide a favorable environment for the
development of Profarma Specialty in Brazil," he concluded.

AmerisourceBergen will purchase up to a 19.9% minority stake by offering
R$22.50 per share for shares offered in a primary offering by Profarma. The
specialty distribution joint venture will include Profarma’s existing
specialty businesses and an equity investment from AmerisourceBergen, and each
company will own a 50% stake in the joint venture.

About AmerisourceBergen

AmerisourceBergen is one of the largest global pharmaceutical sourcing and
distribution services companies, helping both healthcare providers and
pharmaceutical and biotech manufacturers improve patient access to products
and enhance patient care. With services ranging from drug distribution and
niche premium logistics to reimbursement and pharmaceutical consulting
services, AmerisourceBergen delivers innovative programs and solutions across
the pharmaceutical supply channel. With over $100 billion in annualized
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs
approximately 13,000 people. AmerisourceBergen is ranked #32 on the Fortune
500 list. For more information, go to

About Profarma Distribuidora de Produtos Farmacêuticos S.A.

Profarma Distribuidora de Produtos Farmacêuticos S.A. has been engaged for 52
years in the distribution of pharmaceuticals, personal care products and
cosmetics in Brazil's most populous states. In 2013, with the acquisition of
the retail chains Drogasmil/Farmalife and Tamoio, it became one of the largest
mixed distributors in Latin America and the largest in Brazil. With 12
Distribution Centers, Profarma markets approximately 18.0 million units per
month and serves around 33,000 sales outlets. In the pharmaceutical retail
market, it is the tenth largest chain in Brazil, with 140 stores in Rio de
Janeiro. Covering a geographic area that corresponds to 93.5% of the consumer
market for pharmaceutical products in Brazil, Profarma with its specialized
and committed team, aims to be Brazil's largest and most profitable mixed
distributor of pharmaceutical products by delivering consistent and
sustainable results, maintaining low operating costs, strengthening its
competitive advantages and maximizing value for its stockholders. For more
information, go to

AmerisourceBergen's Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this news release are “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Words such as
“expect,” “likely,” “outlook,” “forecast,” “would,” “could,” “should,” “can,”
“will,” “project," “intend,” “plan,” “continue,” “sustain,” “synergy,” “on
track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” “possible,”
“assume,” variations of such words, and similar expressions are intended to
identify such forward-looking statements. These statements are based on
management’s current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance and
are based on assumptions that could prove incorrect or could cause actual
results to vary materially from those indicated. Among the factors that could
cause actual results to differ materially from those projected, anticipated,
or implied are the following: changes in pharmaceutical market growth rates;
the loss of one or more key customer or supplier relationships; the retention
of key customer or supplier relationships under less favorable economics;
changes in customer mix; customer delinquencies, defaults or insolvencies;
supplier defaults or insolvencies; changes in branded and/or generic
pharmaceutical manufacturers’ pricing and distribution policies or practices;
adverse resolution of any contract or other dispute with customers or
suppliers; federal and state government enforcement initiatives to detect and
prevent suspicious orders of controlled substances and the diversion of
controlled substances, federal and state prosecution of alleged violations of
related laws and regulations, and any related litigation, including
shareholder derivative lawsuits or other disputes relating to our distribution
of controlled substances; qui tam litigation for alleged violations of fraud
and abuse laws and regulations and/or any other laws and regulations governing
the marketing, sale, purchase and/or dispensing of pharmaceutical products or
services and any related litigation, including shareholder derivative
lawsuits; changes in federal and state legislation or regulatory action
affecting pharmaceutical product pricing or reimbursement policies, including
under Medicaid and Medicare, and the effect of such changes on our customers;
changes in regulatory or clinical medical guidelines and/or labeling for the
pharmaceutical products we distribute, including certain anemia products;
price inflation in branded and generic pharmaceuticals and price deflation in
generics; greater or less than anticipated benefit from launches of the
generic versions of previously patented pharmaceutical products; significant
breakdown or interruption of our information technology systems; our inability
to realize the anticipated benefits of the implementation of an enterprise
resource planning (ERP) system; interest rate and foreign currency exchange
rate fluctuations; risks associated with international business operations,
including non-compliance with the U.S. Foreign Corrupt Practices Act,
anti-bribery laws and economic sanctions and import laws and regulations;
economic, business, competitive and/or regulatory developments outside of the
United States; risks associated with the strategic, long-term relationship
among Walgreen Co., Alliance Boots GmbH, and AmerisourceBergen, the occurrence
of any event, change or other circumstance that could give rise to the
termination, cross-termination or modification of any of the transaction
documents among the parties (including, among others, the distribution
agreement or the generics agreement), an impact on our earnings per share
resulting from the issuance of the Warrants, an inability to realize
anticipated benefits (including benefits resulting from participation in the
Walgreens Boots Alliance Development GmbH joint venture), the disruption of
AmerisourceBergen’s cash flow and ability to return value to its stockholders
in accordance with its past practices, disruption of or changes in vendor,
payer and customer relationships and terms, and the reduction of
AmerisourceBergen’s operational, strategic or financial flexibility; the
acquisition of businesses that do not perform as we expect or that are
difficult for us to integrate or control; our inability to successfully
complete any other transaction that we may wish to pursue from time to time;
changes in tax laws or legislative initiatives that could adversely affect our
tax positions and/or our tax liabilities or adverse resolution of challenges
to our tax positions; increased costs of maintaining, or reductions in our
ability to maintain, adequate liquidity and financing sources; volatility and
deterioration of the capital and credit markets; natural disasters or other
unexpected events that affect our operations; and other economic, business,
competitive, legal, tax, regulatory and/or operational factors affecting our
business generally. Certain additional factors that management believes could
cause actual outcomes and results to differ materially from those described in
forward-looking statements are set forth (i) in Item 1A (Risk Factors) and
Item 1 (Business) in the Company’s Annual Report on Form 10-K for the fiscal
year ended September 30, 2013 and elsewhere in that report and (ii) in other


AmerisourceBergen Corporation
Barbara Brungess, 610-727-7199
Vice President, Corporate & Investor Relations
Press spacebar to pause and continue. Press esc to stop.